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INTRODUCTION
Functional images using PET (positron emission
tomography) and anatomical images using CT (com-
puted tomography) have traditionally been acquired
in separate sessions. It has been hypothesized that
combining these images leads to improved diagno-
sis and thereby better patient care. The introduction
of a PET/CT system enables both morphological
and metabolic imaging to be performed in a single
session. The PET/CT system has become wide-
spread and plays an important role in clinical on-
cology (1-5).
RADIONUCLIDE
The most commonly used radioisotope for PET im-
aging is fluorine-18, which has a half-life of 109.8 min-
utes and is cyclotron-produced. Fluorine-18 can be
substituted for hydrogen atoms and is most com-
monly used as FDG (fluoro-deoxy-glucose). FDG
uptake reflects glucose metabolism and is based on
the enhanced glycolysis associated with malignant
cells. In malignant cells, the glucose membrane trans-
porter is overexpressed and upregulation of enzyme-
controlling glycolytic pathways occurs. Once taken
up into the cell, FDG is a substrate for hexokinase,
the first enzyme of glycolysis, and is phosphorylated
to FDG-6-phospate. Its metabolic activity ceases and
it remains in the cells (metabolic trapping) ; thus,
its concentration accurately reflects the glycolytic
activity of exogenous glucose. FDG uptake is de-
pendent on many factors, including proliferative ac-
tivity, the number of viable cells, histological grad-
ing, and inflammatory reactions.
FDG-PET/CT SCAN
After fasting for 6 hours, the patient is adminis-
tered 3.7 MBq/kg of FDG intravenously using an
automatic injection system. The blood glucose level
is checked before injection and confirmed to be less
than 150 mg/dl. The patient lies quietly on a bed
in a separate booth during the uptake phase. Water
intake and frequent voiding is recommended, with
the bladder emptied immediately prior to scanning.
The PET/CT scan begins 1 hour after injection of
FDG. Before scanning, the patient is required to re-
move all metal objects from the body (bracelets,
dental braces, etc.) that could cause streak artifacts
on the CT images. The patient is positioned on the
examination table with his/her arms by his/her
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side, and breathes freely throughout the examina-
tion. The PET/CT scan begins with a topogram that
is used to define the axial range of the body. At our
institute, the range is from the top of the head to
the middle of the thigh. The axial ranges of the PET
and CT components of the combined examinations
are matched to ensure fully quantitative attenuation
correction of the emission data ; CT data are used
to confirm anatomical location and for attenuation
correction. In a traditional stand-alone PET system,
a transmission scan would be obtained for attenu-
ation correction, requiring extra time. Once the CT
scan is complete, PET acquisition begins in the
caudal-cranial direction. The entire examination is
completed in 30 minutes or less.
PHYSIOLOGICAL FDG UPTAKE
Fig. 1 shows normal FDG distribution in the
brain (gray matter), pharynx, larynx, thyroid, myo-
cardium, liver, spleen, urinary tract, muscles, bowel,
and genitalia. Distribution varies with the individ-
ual. Brain parenchyma utilizes glucose as an energy
source and usually shows very intense uptake. The
relative uptake in the brain is lower when the blood
glucose level is high because FDG and blood glu-
cose compete for intravascular space (Fig. 2). Myo-
cardial uptake varies from absent to intense. The up-
take can vary even for the same patient at different
times. Myocardial uptake increases in the presence
of insulin. Liver uptake is usually homogenous and
mildly intense, although it may have a mottled ap-
pearance. Mottled uptake may limit the detection
of small lesions. Uptake in the alimentary tract can
be observed in the stomach, small bowel, and co-
lon. Bowel uptake can vary even in the same patient
on different occasions, and can be recognized by lo-
cation and a tubular uptake pattern. Small lesions
can be masked ; focal uptake mimics tumor. CT im-
aging or delayed PET scanning 2 hours after FDG
injection may be helpful to distinguish normal physi-
ological uptake from tumor. Intestinal inflamma-
tion can result in dense FDG uptake. Muscular up-
take varies with insulin level and exercise ; patients
must avoid strenuous exercise on the day before
their PET scan. Bone marrow uptake is generally
low-level. Patients with anemia or those undergo-
ing chemotherapy with colony-stimulating factors
can show diffuse increased uptake that reflects ac-
tivated or recovering bone marrow.
CASE PRESENTATION
In clinical oncology, PET/CT is used to differen-
tiate between malignant and benign lesions, deter-
mine the stage of cancer, monitor the effects of ther-
apy, and detect recurrence. Indications for PET/CT
examination include brain tumors, head and neck
cancers, lung cancer, breast cancer, esophageal can-
cer, colon cancer, pancreatic cancer, metastatic liver
tumors, uterine cancer, ovarian cancer, malignant
lymphoma, malignant melanoma, and cancer of un-
known primary origin.
A 75-year-old male patient with lung cancer un-
derwent PET/CT for staging. The primary lesion
showed intense FDG uptake with hilar and mediasti-
nal lymph node metastasis. No distant metastasis was
detected, and this patient was staged T2N2M0, stage
IIIA (Fig. 3).
A 47-year-old male lymphoma patient was exam-
ined for staging and restaging after four courses of
chemotherapy (Fig. 4). The patient was diagnosed
Fig. 1 PET image of 45 year-old male. Normal FDG distribu-
tion is seen in the brain (gray matter), pharynx, larynx, thyroid,
myocardium, liver, spleen, urinary tract, muscles, bowels and
genitalia.
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as stage IIIa by PET findings. After chemotherapy,
abnormal intense uptake decreased or disappeared.
The regimen was effective and this patient was con-
sidered to be in complete remission.
A 64-year-old female ovarian cancer patient was
examined for tumor marker elevation. Routine CT
examination was unable to distinguish whether the
lesion was recurrent or metastatic ; however, FDG-
Fig. 3 Lung cancer. A 75-year-old male patient with lung cancer was indicated PET/CT for staging. Primary lesion showed intense
FDG uptake with hilar and mediastinal lymph nodes metastasis. No distant metastasis is detected and this patient can be staged T2
N2M0, stage IIIA
Fig. 2 Variations of brain FDG uptake. a) blood sugar level 221 mg/dl, b) blood sugar level 100 mg/dl. The relative uptake in the
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PET/CT demonstrated a recurrent lesion in the pel-
vis. The lesion showed high nodular FDG uptake
corresponding to a soft tissue mass that was difficult
to differentiate from the surrounding normal struc-
tures (Fig. 5).
High-density structures such as metallic dental
dentures and cardiac pacemakers can cause artifacts
on CT (Fig. 6). In the PET/CT system, CT data are
Fig. 5 Recurrence of ovarian cancer. A 65-year-old female ovarian cancer patient was examined for tumor marker elevation. Rou-
tine CT examination was unable to distinguish whether the lesion was recurrent or metastatic ; however, FDG-PET/CT demonstrated
a recurrent lesion in the pelvis. The lesion showed high nodular FDG uptake corresponding to a soft tissue mass that was difficult to
differentiate from the surrounding normal structures.
Fig. 4 Lymphoma. A 47-year-old male lymphoma patient was examined for staging and restaging. a) The patient was diagnosed as
stage IIIa by PET findings. b) After 4 courses of chemotherapy, abnormal intense uptake decreased or disappeared. The regimen
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used for attenuation correction. As positron energy
is much more intense than X ray energy, PET data
are overestimated. It is necessary to review non-
attenuation-corrected PET images in image inter-
pretation. Tongue cancer is unclear in attenuation-
corrected PET images but is clearly demonstrated
in non-attenuation-corrected PET images.
SUMMARY
PET/CT enables metabolic and morphologic im-
ages to be acquired in a single session. The suc-
cess of PET/CT depends on the accurate interpre-
tation of detailed clinical history, with possible
sources being the referring physician, the patient
themselves, and family members. FDG uptake de-
pends on tumor size, malignant cell density, and his-
tological grading. Knowledge of the normal physi-
ologic distribution of FDG and an understanding
of the clinical indications and limitations of PET/CT
enable accurate diagnosis and thus a better level of
care for patients.
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Fig. 6 Dental denture artifact. a) Attenuation-corrected PET image, b) CT image, c) non attenuation-corrected image. The energy
of positron is much higher than X ray, thus PET data is overestimated. Tongue cancer is unclear in attenuation-corrected PET
image, but it clearly demonstrated in non attenuation-corrected PET image.
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